Randomized clinical trial: Effects of Aloe barbadensis Mill. extract on symptoms, fecal microbiota and fecal metabolite profiles in patients with irritable bowel syndrome.

Bani AhluwaliaMaria K MagnussonLena BöhnStine StörsrudFredrik LarssonOtto SavolainenAlastair RossMagnus SimrénLena Öhman

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2020)

In a mixed group of IBS patients, Aloe was not superior to control treatment, although it showed potential to reduce IBS symptom severity in subsets of IBS patients which could be predicted by fecal microbiota and metabolite profiles. ClinicalTrials.gov no: NCT01400048.

Keyphrases

irritable bowel syndrome
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
clinical trial
oxidative stress
climate change